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Nonspeciﬁc anti-inﬂammatory drugs have been purported to reduce the burden of severe inﬂuenza
disease. We demonstrate that, unlike oseltamivir administration, simvastatin administration did not
reduce morbidity, mortality, or viral load of mice infected with H1N1 or H5N1 viruses. No added beneﬁt
to the efﬁcacy of oseltamivir therapy was observed when mice were treated in combination with
simvastatin. Modest reductions in lung cytokine production in H5N1 but not H1N1 virus-infected
simvastatin-treated mice indicate a potential beneﬁt for statin use in mitigating disease following
severe virus infection.
Published by Elsevier Inc.Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors) are a class of cardioprotective medications which
possess pleiotropic immunomodulatory and anti-inﬂammatory
properties (Jain and Ridker, 2005; Kwak et al., 2000). The ability of
statins to inhibit cytokine production, improve endothelial cell
function, and modulate host molecular pathways has led to the
hypothesis that statin use could be a preventative therapy against
cellular damage caused by inﬂuenza virus infection (Blanc et al.,
2011; Fedson, 2006). As statins represent one of the most widely
prescribed classes of drug in the world, identifying the capacity of
statins to reduce inﬂuenza virus morbidity and mortality in the
event of a pandemic or simply to extend the time between onset
of illness and development of severe disease, thus allowing a
greater window for the efﬁcacy of existing antiviral treatments, is
a matter of great public health importance.
Despite conﬂicting reports, several retrospective observational
studies have identiﬁed an association between statin use and
reductions in inﬂuenza virus morbidity in humans; however,
these studies are limited by the substantial variability in timingInc.
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,
are, Suite B3301 Cambridge,and duration of drug administration among participants, or the
inclusion of pneumonia morbidity in the absence of laboratory-
conﬁrmed inﬂuenza virus infection (Brett et al., 2011; Frost et al.,
2007; Kwong et al., 2009; Mortensen et al., 2005; Vandermeer
et al., 2012). Selected animal studies have further suggested
a protective role for statins and other nonspeciﬁc anti-
inﬂammatory drug regimens against acute lung injury, but results
have been mixed (Budd et al., 2007; Ferraro et al., 2011; Gower
and Graham, 2001; Jacobson et al., 2005; Salomon et al., 2007;
Walsh et al., 2011). Recent work has examined the efﬁcacy of
statin treatments following inﬂuenza virus infection in mice,
ﬁnding only limited beneﬁts of statin treatment in the ameliora-
tion of inﬂuenza virus infection, however these studies have not
generally employed contemporary, wild-type viruses and have
not extensively examined statin drugs administered concurrently
with commercially available antiviral treatments (An et al., 2011;
Kumaki et al., 2012; Radigan et al., 2012). Furthermore, incon-
sistencies in statin drug administration, inoculation routes, and a
paucity of studies including inﬂuenza-speciﬁc antivirals as appro-
priate controls among these previously published studies makes
it difﬁcult to thoroughly assess the efﬁcacy of statin administra-
tion in the context of inﬂuenza virus infection. There is a need
to investigate more fully the ability of statin drugs, alone or in
combination with existing antiviral therapeutics, to mitigate
inﬂuenza virus disease severity against both mild and virulent
inﬂuenza virus strains. To address this question, we utilized
simvastatin, a commonly prescribed statin drug, and oseltamivir,
Fig. 1. Effect of statin treatment on inﬂuenza virus disease outcome and replication in mice. Oseltamivir (50 mg/kg), simvastatin (10 mg/kg), or a combination of both was
administered once daily by oral gavage; control mice received vehicle only. (A) Groups of 6–10 mice were inoculated i.n. with 100 MID50 of H5N1 virus and monitored
daily for morbidity and mortality. Any mouse which lost 425% initial body weight was euthanized. (B) Groups of 3–5 mice were inoculated i.n. with 100 MID50 of pH1N1
or H5N1 virus and lungs were collected days 3 and 6 p.i. for virus titration. Tissues were titrated in cells (pH1N1) or eggs (H5N1) with titers reported as plaque forming
units (PFU) or 50% egg infectious doses (EID50)/ml of tissue, respectively. n, po0.05 compared to control mice by one-way ANOVA with a Bonferroni post-test.
Table 1
Kinetic analysis of circulating lymphocytes following H5N1 virus challenge in mice.
WBCb Percentage of circulating lymphocytes in peripheral blooda
LY NE MO EO BA
Pre-infection 2.070.4 76.2 16.7 6.2 0.05 0.3
Day 3
Oseltamivir 2.270.3 75.6n 20.1n 3.3 0.8 0.2
Simvastatin 1.470.5 58.8 33.1 5.7 1.9 0.5
Combo 2.671.3 70.1 25.7 3.4 0.8 0.1
Control 1.270.3 61.8 31.1 5.9 0.7 0.5
Day 6
Oseltamivir 3.671.3n 70.2n 24.0n 5.2 0.5 0.1
Simvastatin 1.170.5 58.9 34.2 3.8 2.4 0.7
Combo 2.271.6 66.9 31.2 1.2 0.6 0.1
Control 1.070.4 49.8 41.6 5.6 2.5 0.6
a Average percentage of lymphocytes (LY), neutrophils (NE), monocytes (MO), eosinophils (EO), and basophils (BA) in whole blood.
b WBC, total white blood cells in whole blood7standard deviation (K/ml).
n po0.05 compared with control group by one-way ANOVA with a Bonferroni post-test.
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(Gubareva et al., 2000; Jain and Ridker, 2005).
To determine the susceptibility of inﬂuenza viruses to statin
treatment in vivo, we inoculated six-to-eight week old female
BALB/c mice intranasally (i.n.) with two viruses which exhibit
divergent phenotypes in this model. A/Chicken/Korea/Gimje/08
(H5N1) replicates efﬁciently in the murine respiratory tract,
causing severe morbidity and mortality (D. Wadford and T.M.Tumpey, unpublished data). A/Mexico/4482/09 (A/H1N1pdm09,
pH1N1) virus, isolated from the 2009 pandemic, does not cause a
lethal infection (Belser et al., 2010). Simvastatin sodium salt
(10 mg/kg body weight; Calbiochem) was administered by oral
gavage once daily for 12 days commencing 72 h before virus
inoculation (Gower and Graham, 2001; Liu et al., 2009). Oselta-
mivir (50 mg/kg body weight; Roche) was administered by oral
gavage once daily for 8 days commencing 24 hours before virus
Fig. 2. Effect of statin treatment on proinﬂammatory cytokine and chemokine production in the lungs of mice following inﬂuenza virus infection. Oseltamivir (50 mg/kg),
simvastatin (10 mg/kg), or a combination of both was administered once daily by oral gavage; control mice received vehicle only. Groups of 3–5 mice were inoculated i.n.
with 100 MID50 of pH1N1 or H5N1 virus and lungs were collected days 3 and 6 p.i. Clariﬁed lung homogenates were tested via BioPlex (Bio-Rad) or ELISA (R&D Systems)
assays. (A) Cytokine and chemokines detected following pH1N1 virus infection. (B) Cytokines and chemokines that were not signiﬁcantly altered by statin treatment
following H5N1 virus infection. (C) Cytokines and chemokines following H5N1 virus infection where signiﬁcant reductions in statin-treated mice compared with control
mice were detected. n, po0.05 compared to control mice by one-way ANOVA with a Bonferroni post-test.
J.A. Belser et al. / Virology 439 (2013) 42–4644inoculation (Tumpey et al., 2002). While these doses are above
concentrations typically administered to humans, they are neces-
sary to achieve bioactive doses in rodents and are consistent with
previously published in vivo studies (Ilyushina et al., 2008; Leung
et al., 2003). Control mice received distilled water on the same
schedule. Mice were inoculated with 100 mouse infectious dose
50% (MID50) of each virus (equivalent to a 2 lethal dose 50%
(LD50) of H5N1), and 6–10 mice/group were monitored daily for
2 weeks for morbidity (measured by weight loss) and mortality.
An additional three to ﬁve mice/group were euthanized on
days 3 and 6 post-inoculation (p.i.) for collection of whole blood
for analysis of circulating lymphocytes, and lung tissues for
virus titration and analysis of proinﬂammatory cytokines and
chemokines (Belser et al., 2010). Days 3 and 6 p.i. were chosenas they represent times of peak viral replication in this model
and are established timepoints for assessment of these para-
meters in murine pathogenesis and antiviral studies (Belser
et al., 2010; Kumaki et al., 2012; Maines et al., 2005; Wong
et al., 2011).
Mice receiving daily statin administration exhibited compar-
able severe morbidity and 100% mortality following a lethal H5N1
virus challenge as untreated control mice (Fig. 1A). In contrast,
oseltamivir treatment protected mice from weight loss and death
following H5N1 virus challenge, and resulted in signiﬁcantly
decreased viral titers in the lung day 6 p.i. (po0.05) (Fig. 1A
and B). The reductions in H5N1 viral load following oseltamivir
treatment are comparable with prior studies demonstrating a
modest decrease in lung virus titer at these times post-infection
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following pH1N1 virus challenge was not observed in any group
tested (o5% of initial body weight loss in any group p.i.).
However, reductions in viral load in the lung were detected
following daily oseltamivir but not simvastatin administration
in these mice (Fig. 1B). Mice receiving a combination of both
simvastatin and oseltamivir did not exhibit an improvement in
disease outcome compared with oseltamivir treatment alone
following infection with either virus subtype. These results are
in agreement with previous studies which found no improvement
in morbidity or mortality following wild-type H5N1 virus infec-
tion in mice treated with immune modulators (Kumaki et al.,
2012; Salomon et al., 2007).
H5N1 virus infection of mice can cause pronounced leukopenia
and lymphopenia, but pretreatment with oseltamivir was found to
protect mice from these hematopoietic alterations (Table 1) (Maines
et al., 2005). In contrast, simvastatin did not protect against leuko-
penia following H5N1 virus infection and did not signiﬁcantly reduce
the degree of lymphocyte depletion compared with control mice
(Table 1). Combination therapy did not confer additional beneﬁt
compared to the respective monotherapies. While simvastatin pre-
treatment of mice contributed to maintaining a normal balance of
immune cell subpopulations following non-virus induced acute lung
injury in a prior study, our ﬁndings are in accord with a recent study
which detected comparable levels of total leukocyte counts in
bronchoalveolar lavage ﬂuid between statin-treated and untreated
control mice following inﬂuenza virus infection (Ferraro et al., 2011;
Radigan et al., 2012).
Previous mouse studies have found that oseltamivir treatment
could reduce lung inﬂammatory responses induced by inﬂuenza
virus infection (Ilyushina et al., 2008; Wong et al., 2011).
Similarly, we found that oseltamivir treatment resulted in the
signiﬁcant reduction of numerous proinﬂammatory cytokines and
chemokines associated with inﬂuenza virus infection, predomi-
nantly following lethal H5N1 virus infection (Fig. 2A, B, and data
not shown) (Maines et al., 2008). Interestingly, simvastatin treat-
ment signiﬁcantly reduced (po0.05) the production of IFNg,
IL-10, and TNFa in the lungs of H5N1 virus-infected mice on
day 3 p.i.; all three cytokines are known targets of statin drugs
with roles in the initiation of inﬂammatory cell inﬁltration
(Fig. 2C) (Jain and Ridker, 2005). Notably, the observed decreased
production of TNFa in statin-treated mice is in agreement with
previous work which has identiﬁed a role for TNFa in inﬂuenza
virus morbidity, with reduced production of TNFa in mice
receiving statins following lung injury in mice (Ferraro et al.,
2011; Szretter et al., 2007). While we observed signiﬁcant reduc-
tions of selected cytokines following statin treatment in H5N1
virus-infected murine lungs, these differences were not observed
following pH1N1 virus-infection (Fig. 2A and data not shown), in
agreement with Radigan et al. who did not observe differences in
cytokine levels in rosuvastatin-treated mice following H3N2 or
H1N1 virus infection (Radigan et al., 2012). No signiﬁcant differ-
ences in cytokine production were detected between mice receiv-
ing oseltamivir alone and those receiving combination therapy
(Fig. 2). Treatment with simvastatin in the absence of virus
infection did not result in substantial alterations of proinﬂamma-
tory cytokines and chemokines compared with uninfected control
mice (data not shown).
Host innate immune responses contribute to the severity
of disease induced by H5N1 viruses, and depletion of cytokines
and/or chemokines can inﬂuence the resulting course of disease
(Maines et al., 2008; Szretter et al., 2007). The ﬁndings in this
report support previous studies which demonstrate limited
improvements in cellular inﬁltration and reduced cytokine pro-
duction in the lungs of mice following administration of immu-
nomodulatory drugs in the absence of improved survival followinglung injury caused by viral, bacterial, and other stimuli (Boyd et al.,
2012; Ferraro et al., 2011; Walsh et al., 2011). While we did not
observe a striking antiviral effect of simvastatin administration
alone following inﬂuenza virus infection, or a measurable improve-
ment of combination therapy over oseltamivir treatment alone in
mice, reduced hypercytokinemia following H5N1 but not pH1N1
virus infection in mice following simvastatin administration sup-
ports a potential beneﬁt of this treatment depending on the virus
used to infect, warranting further study of statin administration in
the mitigation of severe inﬂuenza disease. As shown in animal
studies, reductions in inﬂuenza virus-induced pulmonary inﬂam-
mation by statin administration may be of particular beneﬁt in
severe cases of inﬂuenza virus infection where mechanical ventila-
tion is employed (Muller et al., 2010).Acknowledgments
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